- Home
- GLUE vs PSF Comparison
GLUE vs PSF Comparison
Compare GLUE & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- PSF
- Stock Information
- Founded
- GLUE 2019
- PSF 2010
- Country
- GLUE United States
- PSF United States
- Employees
- GLUE N/A
- PSF N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- PSF Investment Managers
- Sector
- GLUE Health Care
- PSF Finance
- Exchange
- GLUE Nasdaq
- PSF Nasdaq
- Market Cap
- GLUE 308.8M
- PSF 251.0M
- IPO Year
- GLUE 2021
- PSF N/A
- Fundamental
- Price
- GLUE $7.72
- PSF $20.86
- Analyst Decision
- GLUE Buy
- PSF
- Analyst Count
- GLUE 2
- PSF 0
- Target Price
- GLUE $13.50
- PSF N/A
- AVG Volume (30 Days)
- GLUE 2.5M
- PSF 25.0K
- Earning Date
- GLUE 11-06-2025
- PSF 01-01-0001
- Dividend Yield
- GLUE N/A
- PSF 7.69%
- EPS Growth
- GLUE N/A
- PSF N/A
- EPS
- GLUE 0.29
- PSF N/A
- Revenue
- GLUE $177,986,000.00
- PSF N/A
- Revenue This Year
- GLUE $83.76
- PSF N/A
- Revenue Next Year
- GLUE N/A
- PSF N/A
- P/E Ratio
- GLUE $26.24
- PSF N/A
- Revenue Growth
- GLUE 2990.57
- PSF N/A
- 52 Week Low
- GLUE $3.50
- PSF $16.00
- 52 Week High
- GLUE $12.40
- PSF $20.19
- Technical
- Relative Strength Index (RSI)
- GLUE 64.92
- PSF N/A
- Support Level
- GLUE $7.24
- PSF N/A
- Resistance Level
- GLUE $7.87
- PSF N/A
- Average True Range (ATR)
- GLUE 0.40
- PSF 0.00
- MACD
- GLUE 0.02
- PSF 0.00
- Stochastic Oscillator
- GLUE 75.25
- PSF 0.00
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.